ScholarWorks@SUNGKYUNKWAN UNIVERSITY: JUNG, BYONG CHANG

Detailed Information

JUNG, BYONG CHANG (정병창)

Medicine (Medicine)

Research Area

Tel
Homepage

ResearcherID ORCiD Scopus Google Scholar ID ResearchGate

Keyword

Laparoscopy:12||Renal cell carcinoma:11||Nephrectomy:11||Prostate cancer:10||Survival:9||bladder cancer:8||Prostatectomy:8||Urinary bladder neoplasms:8||Prostatic neoplasms:7||prostate cancer:7||Prostate:6||Robotics:6||Magnetic resonance imaging:6||Biopsy:6||renal cell carcinoma:6||Urothelial carcinoma:5||Recurrence:5||Prostatic Neoplasms:5||survival:5||urothelial carcinoma:5||Cystectomy:5||Gleason score:4||Prostate neoplasms:4||Bladder cancer:4||Partial nephrectomy:4||Diagnosis:4||nephroureterectomy:4||Prostatic neoplasm:4||Chemotherapy:3||Kidney:3||Nephroureterectomy:3||nephrectomy:3||Treatment outcome:3||Minimally invasive:3||prostatectomy:3||Docetaxel:3||prognosis:3||Outcomes:3||Prostate biopsy:3||Prostatespecific antigen:3||Carcinoma:3||Focal therapy:2||Metastatic renal cell carcinoma:2||Urinary bladder:2||Repeat biopsy:2||Minimal invasive surgical procedures:2||Biomarkers:2||kidney:2||LESS:2||laparoscopic surgery:2||laparoscopy:2||Robotic:2||Robotic surgical procedures:2||magnetic resonance imaging:2||upper urinary tract:2||Computerized tomography:2||metastatic renal cell carcinoma:2||Prognosticator:2||mortality:2||Hemiablation:2||glomerular filtration rate:2||Cystoscopy:2||Bacillus subtilis:2||Surgery:2||Active surveillance:2||Surgical procedure:2||bladder:2||partial nephrectomy:2||Adrenalectomy:2||pheochromocytoma:2||carcinoma:2||predictor:2||carcinoma, renal cell:2||Targeted biopsy:2||prostate health index:2||Oncologic outcomes:2||Transperineal:2||prostatespecific antigen:2||prostatespecific antigen density:2||Hypertrophy:2||prostatic neoplasm:2||prostatic neoplasms:2||Transrectal ultrasonography:2||Operative surgical procedures:2||Biweekly:2||curcumin:2||cystectomy:2||radical cystectomy:2||Immunotherapy:2||Radical Prostatectomy:2||diagnosis:2||renal cell:2||Outcome:2||Adjuvant:2||Tyrosine kinase inhibitor:2||Female:2||Upper tract urothelial carcinoma:2||adrenalectomy:2||Renal Cell:2||Ureteral obstruction:2||hypertrophy:2||Magnetic Resonance Imaging:1||Malignant disease:1||Metachronous:1||Metanephrine:1||Metastasis:1||Miles’ operation:1||Minimally Invasive Surgical Procedures:1||Minimally invasive surgical procedures:1||Monoclonal antibody:1||Multidetector computed tomography:1||Multidisciplinary team approach:1||Muscleinvasive urothelial bladder cancer:1||Mutation:1||Natural orifice endoscopic surgery:1||Neoadjuvant Therapy:1||Neoadjuvant chemotherapy:1||Neoadjuvant therapy:1||Nephrometry score:1||Nivolumab:1||Nonfunctioning adrenal adenoma:1||Notes:1||Oncological outcome:1||Organ size:1||Osteosarcoma:1||Oxalate:1||Oxalates:1||PTEN:1||Pathology:1||Patient selection:1||Patientderived xenograft:1||Patterns of locoregional recurrence:1||Pentafecta criteria:1||Pentafecta outcome:1||Pheochromocytoma:1||Positive surgical margin:1||Power generation:1||Predictive factor:1||Predictive model:1||Predictors:1||Prior biopsynegative patients:1||Prognosis:1||Prognostic factor:1||Programmed cell death 1 ligand 1:1||Propensity scorematching:1||Prostate Biopsy:1||Prostate Cancer:1||Prostate Imaging Reporting and Data:1||Prostate Imaging Reporting and Data System (PIRADS):1||Prostate ImagingReporting and Data System:1||ProstateSpecific Antigen:1||Prostatespecific antigen density (PSAD):1||Prostatic hyperplasia:1||QMR:1||RCC:1||RLC circuits:1||Radical Cystectomy:1||Radical cystectomy:1||Radical nephrectomy:1||Radical prostatectomy:1||Radical prostatectomy specimen:1||Radiofrequency catheter ablation:1||Radionuclide imaging:1||Radiotherapy:1||Receptor fibroblast growth factor, type 3:1||Renal compensation:1||Renal function:1||Renal insufficiency:1||Republic of Korea:1||Resonant frequency:1||Retropubic:1||Retrospective:1||Risk:1||Risk Assessment:1||Robotassisted laparoscopic partial nephrectomy:1||SOX9:1||Salvage:1||Salvage therapy:1||Sarcoma:1||Sarcopenia:1||Seminal vesicle:1||Sequence analysis:1||Single cell analysis:1||Singlecell RNA sequencing:1||Smoking:1||Subclinical Cushing syndrome:1||Surgical outcomes:1||Surveillance:1||Synchronous:1||Synchronous metastatic renalcell carcinoma:1||System (PIRADS) score:1||Systematic biopsy:1||Systematic random biopsy:1||Systemic inflammatory response:1||TAZ:1||Technetium Tc 99m Pentetate:1||Transitional cell:1||Transitional cell cancer:1||Transperineal US:1||Transrectal ultrasound:1||Transurethral resection of prostate:1||Treatment Outcome:1||Treatment resistance:1||Trend:1||Tumor heterogeneity:1||Tumor microenvironment:1||Tumor volume:1||Tumoral heterogeneity:1||UROPDS:1||Upgrading:1||Upper urinary tract cancer:1||Upper urinary tract urothelial carcinoma:1||Upstaging:1||Ureteroscopy:1||Urethral catheter:1||Urinary Bladder Neoplasms:1||Urinary bladder neck obstruction:1||Urinary diversion:1||Urinary tract infection:1||Urine:1||Urologic surgical procedures:1||Urothelial Carcinoma:1||Urothelial cell carcinoma:1||Vaporization:1||Warm ischaemia:1||Warm ischemia:1||Watchful waiting:1||Whole genome sequencing:1||Wholeexome sequencing:1||Wholetranscriptome sequencing:1||YAP1:1||Yvrk:1||Zero voltage switching:1||abdominal:1||adrenal mass:1||adrenohepatic fusion:1||aldosteronoma:1||androgen receptor:1||androgen receptor variant 7:1||artesunate:1||aspartate transaminase/alanine transaminase (De Ritis) ratio:1||biochemical recurrence:1||biomarker:1||biopsy:1||body mass index:1||bone metastasis:1||bruceantin:1||c:1||calculi:1||castrationresistant:1||castrationresistant prostate cancer:1||chemotherapy:1||chronic kidney disease:1||cisplatin:1||clinical practice pattern:1||clinical trials:1||clinically insignificant prostate cancer (CIPC):1||compensation:1||complications:1||computed tomography:1||cysts:1||detection:1||diabetic nephropa:1||diverticulum:1||docetaxel:1||drug repurposing:1||drug screening:1||early detection of cancer:1||employment:1||endoscopy:1||enzalutamide resistance:1||erythrocyte sedimentation rate:1||functional and oncological outcomes:1||health screening:1||high efficiency:1||highfrequency fullbridge inverter:1||hypertension:1||immune cell:1||immune checkpoint:1||immune checkpoint inhibitor:1||immune checkpoint inhibitors:1||immunohistochemistry:1||immunosurveillance:1||immunotherapy:1||intermittent androgen deprivation:1||internal organ retractor:1||intraoperat:1||kidney function:1||laparoendoscopic singlesite surgery:1||large renal tumors:1||lymphovascular invasion:1||m:1||mTOR:1||mediator complex subunit 12:1||metanephrine:1||metastasis:1||minimally invasive surgical procedures:1||molecular features:1||mpMRI:1||multiparametric magnetic resonance imaging:1||muscle invasive bladder cancer:1||mutation analysis:1||natural killer cell activity:1||negative predictive value:1||neoplasm metastasis:1||neoplasm metastasis, local:1||neutrophillymphocyte ratio:1||nomogram:1||obesity:1||oncologic outcome:1||oncosis:1||overall survival:1||oxidative stress:1||paraganglioma:1||patientderived xenograft:1||pediatrics:1||postoperative complications:1||practice guideline:1||prediction model:1||programmed cell deathligand 1:1||propensity score:1||propensity score matched analysis:1||propensityscore matching analysis:1||prostate health index density:1||prostate imaging and reporting and data system:1||prostate imaging reporting and data system:1||prostate neoplasms:1||prostatic neo:1||proteintyrosine kinases:1||proteinuria:1||psychooncology:1||quality of life:1||quantum molecular resonance:1||radical nephrectomy:1||radical prostatectomy:1||radiofrequency ablation:1||recurrence:1||renal function:1||renal volume:1||resonant filter:1||responsiveness:1||risk:1||robot cystectomy:1||robotassisted surgery:1||robotic:1||robotic partial nephrectomy:1||robotic surgery:1||robotic surgical procedure:1||robotic surgical procedures:1||robotics:1||salvage radiotherapy:1||salvage therapy:1||selection bias:1||simple nephrectomy:1||social stigma:1||statistics:1||sunitinib:1||surgical energy device:1||surgical margin:1||surgical smoke:1||survey:1||survival outcomes:1||survival rate:1||survivorship:1||tomography, xray computed:1||transhepatic radiofrequency ablation:1||transperineal prostate biopsy:1||transrectal ultrasound:1||treatment outcome:1||trend:1||tyrosine kinase inhibitor:1||tyrosine kinase inhibitors:1||upper tract urothelial carcinoma:1||urachal carcinoma:1||urethral recurrence:1||urinary bladder neoplasm:1||urinary diversion:1||urinary tract:1||urothelium cancer:1||vessel sealing technologies:1||von HippelLindau (VHL):1||wide load impedance range:1||#BladderCancer:1||zerovoltage switching (ZVS):1||#blcsm:1||#uroonc:1||AKT:1||ALT:1||ARV7:1||AST:1||AZD2014:1||AZD5363:1||Abiraterone acetate:1||Adjuvant chemotherapy:1||Adolescent:1||Adrenal incidentaloma:1||Advancement:1||Apparent diffusion coefficient:1||Approach:1||Atezolizumab:1||AttentionDeficit/Hyperactivity Disorder and Imaging/Imaging Studies:1||B:1||BEZ235:1||Benign prostatic hyperplasia:1||Benign prostatic obstruction:1||Biochemical recurrence:1||Biopsy outcomes:1||Biopsy techniques:1||Biopsynaive patients:1||Bladder Cancer:1||Bladder cuff method:1||Bladder neoplasm:1||Bladder wall thickening:1||Body Mass Index:1||COX2 inhibitors:1||Camellia sinensis var. assamica:1||Cancer:1||Carcinoma, Renal cell:1||Castrateresistant prostate cancer:1||Castrationnaïve prostate cancer:1||Chronic kidney disease:1||Circulating tumor DNA:1||Cisplatin:1||Clinical stage:1||Combination:1||Competing risk analysis:1||Complication:1||Complications:1||Computed tomography:1||Concurrent chemoradiotherapy:1||Cytology:1||Cytoreductive nephrectomy:1||DNA:1||Diagnostic imaging:1||Diffusionweighted MRI:1||Dissection:1||Downgrading:1||Drug response:1||Dual blockade:1||EGFR:1||ERG:1||ERK:1||Early death:1||East Asia:1||Electrosurgical generator (ESG):1||Equine Assisted Activities and Therapy:1||Extracorporeal shockwave lithotripsy:1||Extraprostatic extension:1||Extraskeletal:1||Factor:1||Functional outcomes:1||GaN switch:1||Genetic counseling:1||Glomerular filtration rate:1||HSP90:1||Hemainolevulinate:1||Heng risk criteria:1||High grade:1||Highintensity focused ultrasound ablation:1||Histological characteristics:1||Holmium laser enucleation of prostate:1||Hyperoxaluria:1||IMDC poorrisk:1||Impedance:1||Insignificant:1||Inverters:1||Kidney function test:1||Kidney neoplasm:1||Kidney transplantation:1||Kidney volume:1||Laparoscopic adrenalectomy:1||Laparoscopic partial nephrectomy:1||Laparoscopic surgery:1||Laser vaporization prostatectomy:1||Lasers:1||Learning curve:1||Living donor:1||Locallyadvanced:1||Locoregional recurrence:1||Longterm surveillance:1||Lymph Node Dissection:1||Lymph Node Metastasis:1||Lymph node excision:1||MRI:1||

STATISTICS: Total View :5,233,678; Today View :1,715

RSS_1.0 RSS_2.0 ATOM_1.0

(03063) 25-2, SUNGKYUNKWAN-RO, JONGNO-GU, SEOUL, KOREAsamsunglib@skku.edu

Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.

Detailed Information

Keyword

BROWSE